Elevated Neutrophil-Lymphocyte Ratio Linked to Worse Prostatectomy Outcomes

Share this content:
Elevated neutrophil-lymphocyte ratio prior to radical prostatectomy for prostate cancer significantly associated with biochemical recurrence.
Elevated neutrophil-lymphocyte ratio prior to radical prostatectomy for prostate cancer significantly associated with biochemical recurrence.

NEW ORLEANS—An elevated neutrophil-lymphocyte ratio (NLR) prior to radical prostatectomy for prostate cancer is significantly associated with higher rates of biochemical recurrence and positive surgical margins, data presented at the American Urological Association annual meeting suggest.

Compared with patients who have an NLR below 5, those with an NLR above 5 have a significant 13% increased risk of biochemical recurrence at 10 years.

Vidit Sharma, MD, of Mayo Clinic in Rochester, Minn., and colleagues identified 8,350 RP patients who had a median follow-up of 9.7 years. Of these, 1,568 (18.7%) had a pre-RP NLR above 5.

These patients were significantly more likely than those with an NLR below 5 to have pT3/4 disease at RP (22% vs. 17.1%) and positive surgical margins (33.2% vs. 25.8%) and significantly more likely to receive adjuvant hormonal therapy (13.8% vs. 8.2%) and radiation therapy (4.7% vs. 3.2%).

Patients with an NLR above 5 also were significantly more likely to receive salvage hormonal therapy during follow-up (14% vs. 11.4%).

RELATED: Prostate Cancer Metastasis Predictors in Active Surveillance Patients Identified

After controlling for age, Gleason score, preoperative PSA level, pathologic state, and use of adjuvant hormonal or radiation therapy, an NLR above 5 remained a significant predictor of biochemical recurrence, according to investigators.

An elevated NLR is a marker of systemic inflammation that is associated with adverse outcomes in multiple malignancies.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs